Mary McCormack: Profile

Dr Mary McCormack is a Consultant Clinical Oncologist at University College London Hospitals NHS Trust where she is the Senior Clinical Oncologist in gynaecological cancer. Specialising in gynaecological and breast cancers, she offers private cancer treatment (chemotherapy and radiotherapy) at leading private hospitals in the Harley Street area.

Dr McCormack sees private patients all day Fridays along with some evenings (flexible times). If you would like to get in contact with her please go to the contacts page. Her initial consultation fee is up to £350. Additionally, any follow up consultations after wil not exceed £250.


Dr Mary McCormack qualified from the United Medical and Dental Schools of Guy’s and St Thomas’ Hospitals (UMDS), London in 1993. Prior to undertaking her medical training, in 1989 she was awarded a PhD for her research work in radiation biology.

Dr McCormack has worked in some of London’s top cancer centres and was awarded the Fellowship of the Royal College of Radiologists (FRCR) in Clinical Oncology in 2000. She was appointed as a consultant at University College London Hospitals NHS Trust in 2002. She is she Chair of the Cervical Cancer Research Network (International) and an executive member of the Gynaecological Cancer Intergroup (GCIG).

Clinical interests

Dr McCormack is a recognised expert in both chemotherapy and radiotherapy. She specialises in the treatment of gynaecological cancers, including ovarian, cervical, womb (endometrial), vulva and vaginal cancer, as well as cancers affecting the breast.

Research interests

Actively involved in research, Dr McCormack is a major contributor to national and international clinical trials. Her research interests include the treatment of cervical cancer, fertility and cancer therapy and targeted therapy in endometrial and ovarian cancer agents in breast and gynaecological cancer and radiation injury to the bowel.


Eminowicz G, Motlib J,Khan S, Perna C and McCormack M, Pelvic organ motion during Radiotherapy for Cervical Cancer: understanding patterns and recommended patient preparation. Clinical Oncology E Pub, vol 28 issue 9 Sept 2016

Eminowicz G, Rompokos V,Stacey S and McCormack M, The dosimetric impact of target volume delineation variation for cervical cancer radiotherapy. Radiotherapy and Oncology Published on line 6 May 2016

Eminowicz G, Hall-Craggs M, Diez P and McCormack M, Improving target volume delineation in intact cervical cancer; literature review and step-by-step pictorial atlas to aid contouring. Practical Radiation Oncology 2016, Jan, Epub ahead of print

Eminowicz G, McCormack M, Variability of clinical target volume delineation for definitive radiotherapy in cervix cancer. Radiother Oncol 2015 Oct 13 Epub ahead of print

Symonds RP,Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M et al, Cediranibcombined with carboplatin and paclitaxel chemotherapy in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double- blind, placebo- controlled phase 2 trial. Lancet Oncol.2015 Oct 13 Epub ahead of print

Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwatrz B, Cheng J, Li X, Campbell K, Dodion P, Haluska FG, Randomized Phase II Trial of ridaforolimus in Advanced Endometrial Carcinoma. J Clin Oncol. 2015 Jun 15 Epub ahead of print

Kuku S, Proctor I, Loddo M, Kadalayil L, KhoshZaban M, Ledermann J, McCormack M, Do cell- cycle phase –specific markers predict disease grade,stage and outcome in cervical carcinoma? Int J Gynaecol Cancer: 2015; Jul; 25(6):1066-72

Lanceley A, Fiander A, McCormack M, Bryant A, Follow-up protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev. 2013 Nov 25; 11

Kuku S, Fragkos C, McCormack M, Forbes A, “Radiation-induced bowel injury: The impact of radiotherapy on survivorship after treatment for gynaecological cancers.”  Brit.J.Cancer 2013 Sept; 109:1504-1512

Kuku S, Williams M, McCormack M, et al. Adjuvant Therapy in Stage III endometrial Cancer: Treatment Outcomes and survival.  A Single Institution Retrospective Study – Int.J Gynecol Cancer 2013 Jul; 23(6):1056-64

McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Lederman J, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer – Brit.J.Cancer 2013 Jun, 108(12):P.2464

Guth U, Hadwin RJ, Schotzau A, McCormack M, “Clinical outcomes and patterns of severe late toxicity in the era of chemo-radiation for cervical cancer”- Arch.Gynecol Obstet 2012 June; 285(6):1703-11

Saha A, Varughese M, Gallagher C, Orphanos G, Oram D, Jeyerajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann J, Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery” – Int.J Gynecol Cancer 2012 May; 22, 4:1-7

Mahil S, Marks D, McCormack M, Rahman A - Dermatomyositis. British Journal of Hospital Medicine 2012 Feb; 73(2); C18-C22

Viswanathan AN, Creutzber C, Craighead P, McCormack M, et al. International Brachytherapy Practice: A Survey of the Gyn Cancer Intergroup GCIG. Int.J.Rad.Oncol.Biol.Physics 2012 Jan 1; 82(1):250-255

le Grange F, McCormack M.  Cervical Cancer during Pregnancy – An approach to diagnosis and management.  Current Women’s Health Reviews 2011, 7, 1:82

Guth U, Ella W, Olaitan A, Hadwin R, Arora R, McCormack M. Total vaginal necrosis: A representative example of underreporting severe late toxic reaction after concomitant chemoradiation for cervical cancer. Int.J.Gynecol Cancer 2010; 20: 54-60

A Silvanto, McCormack M, R Arora, Nuclear Thyroid Transcription Factor (TTF-1) Expression in Endometrial Carcinoma. Pathological Society of Great Britain Annual Meeting 08.01.2008

Olaitan A, McCormack M, Centralisation of services for the management of ovarian cancer: arguments for. Br Journal Obstetrics and Gynaecology 2007; 114: 1188-1190